Corpusense

Zimmer Biomet (ZBH) earnings call transcript summary & sentiment

Last call Wed 5 Aug 2026

Our read on the 5 August 2026 earnings call

Overall tone: Positive

Overall tone

Positive

Executive Summary

Zimmer Biomet delivered strong second-quarter results, posting net sales of $2.177 billion representing 4.0% organic constant currency growth, led by 5.9% U.S. hip growth and over 50% growth in U.S. technology sales.

Core Signals

Revenue Growth & Demand: Organic constant currency revenue grew 4.0% in Q2, propelled by 4.6% growth in the U.S. and 3.1% internationally.

Bullish Signals

Full-year organic constant currency revenue growth guidance was upgraded to 2.25%-3.25%, accompanied by an raised adjusted EPS target of $8.47-$8.59.

Risk Signals

Adjusted operating margin declined 210 basis points YoY to 25.7%, with full-year operating margin now projected to contract slightly over 50 basis points.

Q&A Signals

Repeated analyst topics: Analysts repeatedly inquired about U.S. sales force transition productivity, broader orthopedic procedural trends, and preliminary growth drivers for 2027.

Key Investor Debate

The fundamental investor debate revolves around whether Zimmer Biomet's near-term margin dilution from heavy SG&A sales force investments will yield sustainable, market-share-gaining top-line acceleration in 2027 and beyond.

Analyst Takeaway

Zimmer Biomet demonstrated resilient execution, proving that its U.S. sales force transformation is progressing with lower turnover and less customer disruption than initially feared.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Zimmer Biomet and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Zimmer Biomet's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Zimmer Biomet, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Zimmer Biomet say about margins, and did the framing change from last quarter?"

"Did Zimmer Biomet's management walk back any full-year guidance, and how did they frame it?"

"Where did Zimmer Biomet avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

Every one at 08:30 ET, before the open.

Date Day Period Corpusense read
2026-08-05Wednesday2026 Q3Positive
2026-04-28Tuesday2026 Q2Neutral to cautiously optimistic
2026-02-10Tuesday2026 Q1Mixed
2025-11-05Wednesday2025 Q4—
2025-08-07Thursday2025 Q3—
2025-05-05Monday2025 Q2—
2025-02-06Thursday2025 Q1—

Earnings calls across Health Care Equipment & Supplies

The companies Zimmer Biomet is read alongside. Each has its own earnings call dates and sentiment.

ABTAbbott LaboratoriesALGNAlign TechnologyBAXBaxter InternationalBDXBecton DickinsonBSXBoston ScientificCOOCooper Companies (The)DXCMDexcomEWEdwards Lifesciences

Zimmer Biomet is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing